Premium
Chromosome 8 markers of metastatic prostate cancer in African American men: Gain of the MIR151 gene and loss of the NKX3‐1 gene
Author(s) -
Barnabas Nandita,
Xu Lihua,
Savera Adnan,
Hou Zizheng,
Barrack Evelyn R.
Publication year - 2010
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.21302
Subject(s) - prostate cancer , prostatectomy , medicine , prostate , oncology , cancer , androgen receptor , primary tumor , prostate specific antigen , cancer research , metastasis , pathology
BACKGROUND Radical prostatectomy (RP) is not curative if patients have undetected metastatic prostate cancer. Markers that indicate the presence of metastatic disease would identify men who may benefit from systemic adjuvant therapy. Our approach was to analyze the primary tumors of men with metastatic disease versus organ‐confined disease to identify molecular changes that distinguish between these groups. METHODS Patients were identified based on long‐term follow‐up of serum prostate specific antigen (PSA) levels following RP. We compared the tumors of African American (AA) men with undetectable serum PSA for >9 year after RP (good outcome) versus those of AA men with a rising PSA and recurrence after radiation or androgen ablation or both (poor outcome). We used real‐time quantitative PCR to assay gene copy number alterations in tumor DNA relative to patient‐matched non‐tumor DNA isolated from paraffin‐embedded tissue. We assayed several genes located in the specific regions of chromosome 8p and 8q that frequently undergo loss and/or gain, respectively, in prostate cancer, and the androgen receptor gene at Xq12. RESULTS Gain of the MIR151 gene at 8q24.3 (in 33% of poor outcome vs. 6% of good outcome tumors) and/or loss of the NKX3‐1 gene at 8p21.2 (in 39% of poor outcome vs. 11% of good outcome tumors) affected 67% of poor outcome tumors, compared to only 17% of good outcome tumors. CONCLUSIONS Copy number gain of the MIR151 gene and/or loss of the NKX3‐1 gene in the primary tumor may indicate the presence of metastatic disease. Prostate 71:857–871, 2011. © 2010 Wiley‐Liss, Inc.